No­var­tis chief Jimenez touts two top PhI­II drug prospects

No­var­tis CEO Joe Jimenez has been busy giv­ing in­ter­views at Davos this week.

In a sit-down with Reuters the Basel-based ex­ec not­ed that Trump’s tax poli­cies could help set the stage for build­ing new man­u­fac­tur­ing fa­cil­i­ties in the US. And he al­so tapped two late-stage drugs as among his fa­vorites in the pipeline.

Those two fa­vorites are CTL-019, the pi­o­neer­ing CAR-T that No­var­tis is steer­ing to a near-term ap­pli­ca­tion at the FDA, and BAF-312 for sec­ondary pro­gres­sive mul­ti­ple scle­ro­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.